A P Chen
National Cancer Institute LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name A P Chen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:07 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05836571 · Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO · active not recruiting · Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma · principal investigator
- Ph2NCT05333458 · Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialNational Cancer Institute (NCI) · recruiting · Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma · principal investigator
- Ph2NCT05142241 · Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 TrialNational Cancer Institute (NCI) · active not recruiting · Malignant Solid Neoplasm · principal investigator
- Ph2NCT04550494 · Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNational Cancer Institute (NCI) · active not recruiting · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma · principal investigator
- Ph2NCT04458922 · Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced ChondrosarcomaNational Cancer Institute (NCI) · active not recruiting · Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma · principal investigator
- Ph2NCT03907475 · Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialNational Cancer Institute (NCI) · recruiting · Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT03502733 · Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaNational Cancer Institute (NCI) · active not recruiting · Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
- Ph2NCT01827384 · MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene VariationsNational Cancer Institute (NCI) · completed · Advanced Malignant Solid Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 378 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:07 UTC. The ranking covers the 200 most relevant of 80 PubMed records, and a shared surname and initials can bring in a namesake. All 80 on PubMed
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.J Clin Oncol · 2020341 citationsRCR 14.0
- 305 citationsRCR 12.3
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.J Clin Oncol · 2015287 citationsRCR 7.6
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).J Clin Oncol · 2020242 citationsRCR 8.4
- 183 citationsRCR 3.5
- Atezolizumab for Advanced Alveolar Soft Part Sarcoma.N Engl J Med · 2023148 citationsRCR 11.6
- Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).J Clin Oncol · 2017142 citationsRCR 4.4
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.Eur J Cancer · 2018135 citationsRCR 4.2
- Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.J Clin Oncol · 2020129 citationsRCR 5.0
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol · 2020115 citationsRCR 4.1